GlioCART Raises CHF 150,000 Seed Funding to Accelerate Innovative Glioblastoma CAR‑T Therapy
GlioCART, the Swiss biotech start‑up spun out of the University of Basel, has secured early seed funding support that is helping to accelerate development of its innovative CAR‑T cell therapy for glioblastoma, one of the most aggressive and treatment‑resistant forms of brain cancer. The fledgling company has received CHF 150,000 from the Venture Kick programme — a Swiss seed funding initiative that provides capital, mentoring and ecosystem connections to promising early‑stage ventures — to support strategic development, strengthen intellectual property and foster partnerships aimed at advancing its dual‑mode immunotherapy toward commercialisation.
Founded in late 2025 and headquartered in Allschwil, Switzerland, GlioCART is developing a next‑generation cell therapy designed to tackle both glioblastoma tumors and their immunosuppressive microenvironment — a key barrier that has limited the effectiveness of conventional therapies such as surgery, radiotherapy and chemotherapy. The company’s engineered immune cells not only recognise and kill cancer cells but are also programmed to re‑educate immune cells in the tumor’s surrounding environment, potentially offering a more durable and effective treatment option for patients with glioblastoma, whose median survival remains around 15 months under current standard‑of‑care treatments.
The CHF 150,000 from Venture Kick marks a significant early milestone for GlioCART as it transitions from research prototypes toward translational development. Venture Kick’s model is designed to help early‑stage biotech ventures build a strong corporate foundation and attract follow‑on investment through staged funding, support and preparation for future fundraising rounds. GlioCART’s award builds on earlier support from the University of Basel’s Propelling Grant of CHF 50,000 in 2024, which helped kickstart initial research and establish momentum for the project.
Venture Kick’s backing is considered especially meaningful in the Swiss biotech ecosystem, where early capital and structured support can help nascent scientific ventures navigate the challenging path from laboratory discovery to clinical and commercial validation. The CHF 150,000 award enables GlioCART to sharpen its development strategy, engage with potential pharmaceutical collaborators and begin laying groundwork that could support eventual clinical trial progression and regulatory engagement.
The founding team, comprising CEO Dieter Willmann, Chief Medical Officer Prof. Dr. Gregor Hutter, COO Dr. Patrice Zeis and CSO Dr. Valerio Sabatino, unites expertise across corporate strategy, translational research, immuno‑oncology and data science. Their collective experience positions the company to address some of the most complex challenges in cancer therapy development and to communicate effectively with investors, partners and regulatory stakeholders as the programme advances.
GlioCART’s approach has drawn attention not only for its therapeutic potential but also for addressing a substantial unmet medical need. With approximately 80,000 new glioblastoma cases diagnosed annually worldwide and a limited set of curative options, there is a significant addressable market valued at an estimated USD 3 billion today and projected to grow to USD 6 billion by 2033. This combination of therapeutic need and market potential underscores why early strategic funding through a programme like Venture Kick can be impactful for the start‑up’s future investment prospects.
The dual action of GlioCART’s therapy — targeting both the tumor and its protective immune environment — represents a broader trend in cancer immunotherapy where developers aim to overcome resistance mechanisms that have historically limited success in solid tumors. Should GlioCART’s technology continue to demonstrate promise through translational studies, it could pave the way for larger institutional or strategic investments from biotech and pharmaceutical partners keen to advance next‑generation cell therapies into clinical settings.
While the CHF 150,000 seed award does not represent a traditional equity funding round, it is an important catalytic investment for the company’s early trajectory. Venture Kick’s staged support model often helps Swiss start‑ups prepare for subsequent rounds of institutional venture capital or corporate investment, and GlioCART’s success in securing this initial seed funding positions it to continue engaging with the broader investment community as it progresses toward proof of concept and potential regulatory milestones.
As GlioCART pushes forward with its R&D and strategic engagements, the company is poised to continue strengthening its scientific foundation and investor appeal, laying the groundwork for future funding that could support clinical validation and global access to its innovative glioblastoma therapy.
